Logo image of CMMB

CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Overview

USA - NASDAQ:CMMB - US16385C2035 - ADR

2.91 USD
-0.18 (-5.83%)
Last: 10/23/2025, 8:00:01 PM
3 USD
+0.09 (+3.09%)
After Hours: 10/23/2025, 8:00:01 PM

CMMB Key Statistics, Chart & Performance

Key Statistics
Market Cap54.87M
Revenue(TTM)N/A
Net Income(TTM)-11826000
Shares18.86M
Float741.80K
52 Week High9.84
52 Week Low2.39
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.76
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12
IPO2012-08-14
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CMMB short term performance overview.The bars show the price performance of CMMB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

CMMB long term performance overview.The bars show the price performance of CMMB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of CMMB is 2.91 USD. In the past month the price increased by 16.4%. In the past year, price decreased by -49.48%.

CHEMOMAB THERAPEUTICS LTD / CMMB Daily stock chart

CMMB Latest News, Press Relases and Analysis

CMMB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.55 403.22B
AMGN AMGEN INC 13.43 157.68B
GILD GILEAD SCIENCES INC 15.6 149.82B
VRTX VERTEX PHARMACEUTICALS INC 24.95 108.36B
REGN REGENERON PHARMACEUTICALS 12.61 61.02B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.82B
ARGX ARGENX SE - ADR 88.18 50.01B
ONC BEONE MEDICINES LTD-ADR 5.01 34.05B
INSM INSMED INC N/A 33.84B
NTRA NATERA INC N/A 26.76B
BNTX BIONTECH SE-ADR N/A 25.18B
BIIB BIOGEN INC 9.37 22.00B

About CMMB

Company Profile

CMMB logo image Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Company Info

CHEMOMAB THERAPEUTICS LTD

Kiryat Atidim, Building 7

TEL AVIV-YAFO 02139 IL

CEO: Neil Cohen

Employees: 20

CMMB Company Website

CMMB Investor Relations

Phone: 972773310156

CHEMOMAB THERAPEUTICS LTD / CMMB FAQ

What is the stock price of CHEMOMAB THERAPEUTICS LTD today?

The current stock price of CMMB is 2.91 USD. The price decreased by -5.83% in the last trading session.


What is the ticker symbol for CHEMOMAB THERAPEUTICS LTD stock?

The exchange symbol of CHEMOMAB THERAPEUTICS LTD is CMMB and it is listed on the Nasdaq exchange.


On which exchange is CMMB stock listed?

CMMB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CHEMOMAB THERAPEUTICS LTD stock?

9 analysts have analysed CMMB and the average price target is 30.26 USD. This implies a price increase of 939.86% is expected in the next year compared to the current price of 2.91. Check the CHEMOMAB THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CHEMOMAB THERAPEUTICS LTD worth?

CHEMOMAB THERAPEUTICS LTD (CMMB) has a market capitalization of 54.87M USD. This makes CMMB a Micro Cap stock.


How many employees does CHEMOMAB THERAPEUTICS LTD have?

CHEMOMAB THERAPEUTICS LTD (CMMB) currently has 20 employees.


What are the support and resistance levels for CHEMOMAB THERAPEUTICS LTD (CMMB) stock?

CHEMOMAB THERAPEUTICS LTD (CMMB) has a support level at 2.67 and a resistance level at 3.29. Check the full technical report for a detailed analysis of CMMB support and resistance levels.


Should I buy CHEMOMAB THERAPEUTICS LTD (CMMB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CHEMOMAB THERAPEUTICS LTD (CMMB) stock pay dividends?

CMMB does not pay a dividend.


When does CHEMOMAB THERAPEUTICS LTD (CMMB) report earnings?

CHEMOMAB THERAPEUTICS LTD (CMMB) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of CHEMOMAB THERAPEUTICS LTD (CMMB)?

CHEMOMAB THERAPEUTICS LTD (CMMB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.76).


CMMB Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to CMMB. When comparing the yearly performance of all stocks, CMMB is a bad performer in the overall market: 95.34% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CMMB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CMMB. While CMMB has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CMMB Financial Highlights

Over the last trailing twelve months CMMB reported a non-GAAP Earnings per Share(EPS) of -2.76. The EPS increased by 93.48% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -106.26%
ROE -121.93%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%64.6%
Sales Q2Q%N/A
EPS 1Y (TTM)93.48%
Revenue 1Y (TTM)N/A

CMMB Forecast & Estimates

9 analysts have analysed CMMB and the average price target is 30.26 USD. This implies a price increase of 939.86% is expected in the next year compared to the current price of 2.91.


Analysts
Analysts84.44
Price Target30.26 (939.86%)
EPS Next Y94.09%
Revenue Next YearN/A

CMMB Ownership

Ownership
Inst Owners15.9%
Ins Owners11.37%
Short Float %N/A
Short Ratio0.8